Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
ADMA Biologics stock has jumped 13% in a week, so why does the August 10 lawsuit deadline still matter?
ADMA Biologics is approaching an August 10 lead-plaintiff deadline in a securities class action at a moment when stronger ASCENIV sales, higher margins and improved cash generation are complicating the investment narrative.
Avacta (AIM: AVCT) share count rises 27.7% as ÂŁ41.5m funding cycle splits between trials and debt
Avacta Group Plc has added approximately 102.3 million ordinary shares since the end of 2024, reducing a non-participating holder’s proportional ownership by about 21.7% while financing clinical development and lowering convertible-bond principal.
Oxford Biomedica (LSE: OXB) plunges 15% as 2026 revenue guidance falls
Oxford Biomedica cut 2026 revenue guidance by £40m at midpoint. September results must show whether OXB’s setback is timing or something deeper.
Lexeo’s second cardiac gene therapy gains FDA support ahead of year-end update
LX2020 gains FDA RMAT status after early heart gene therapy data, strengthening Lexeo’s regulatory path ahead of a key 12-month update.
Early lung cancer responses push ACR-2316 into a broader randomized trial
ACR-2316 enters randomized expansion after durable lung cancer activity. Read how the six-tumor study could reshape Acrivon’s outlook.
Harmony’s next growth engine takes shape as BP-205 clears its first clinical test
BP-205 shows a 25-hour half-life as Harmony uses record WAKIX revenue to fund its next neuroscience growth engine amid rising orexin competition
One-time gene correction therapy BEAM-302 reaches pivotal AATD testing
BEAM-302 enters pivotal AATD testing as Beam Therapeutics targets accelerated approval with $1.2 billion in cash and new data due in September.
FDA opens first human test for BriaCell’s prostate cancer cell therapy
Bria-PROS+ gains FDA clearance for its first prostate cancer trial, expanding BriaCell’s off-the-shelf cellular immunotherapy platform.
NIH backs Greenstone Biosciences iPSC and AI programme for Duchenne cardiomyopathy
Greenstone Biosciences has secured a National Institutes of Health R61 award to discover potential treatments for cardiac fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy, extending its patient-derived stem-cell drug discovery strategy into one of the disease’s most consequential complications.
Greenstone Biosciences wins NHLBI R61 award to identify small-molecule treatments for DMD heart disease
Greenstone Biosciences has secured a $625,968 National Heart, Lung, and Blood Institute (NHLBI) R61 grant to combine patient-derived stem cells, proteomics and artificial intelligence in the search for small-molecule treatments for cardiac fibrosis in Duchenne muscular dystrophy (DMD). The award validates the company’s human-cell-based discovery platform, but target selection, compound validation and progression into the programme’s R33 phase remain critical tests.